{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:43:19Z","timestamp":1785670999266,"version":"3.56.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","award":["08TGF-1257"],"award-info":[{"award-number":["08TGF-1257"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EU FP7 HEALTH-F2-2010-242114"],"award-info":[{"award-number":["EU FP7 HEALTH-F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Education and Research","award":["01EE1407A"],"award-info":[{"award-number":["01EE1407A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.biopsych.2015.11.018","type":"journal-article","created":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T11:45:13Z","timestamp":1448711113000},"page":"604-612","source":"Crossref","is-referenced-by-count":78,"title":["Therapeutic Potential of Cannabinoids in Psychosis"],"prefix":"10.1016","volume":"79","author":[{"given":"F. Markus","family":"Leweke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane K.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Rohleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2015.11.018_bib1","series-title":"Du hachisch et de l\u2019ali\u00e9nation Mentale","author":"Moreau de Tours","year":"1845"},{"key":"10.1016\/j.biopsych.2015.11.018_bib2","first-page":"337","article-title":"Zur Klinik des Haschischrausches","volume":"5","author":"Beringer","year":"1932","journal-title":"Nervenarzt"},{"key":"10.1016\/j.biopsych.2015.11.018_bib3","first-page":"705","article-title":"Marihuana","volume":"18","author":"Adams","year":"1942","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.biopsych.2015.11.018_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02163886","article-title":"Hashish","volume":"2","author":"Todd","year":"1946","journal-title":"Experientia"},{"key":"10.1016\/j.biopsych.2015.11.018_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1176\/ajp.99.2.248","article-title":"The psychiatric aspects of marihuana intoxication","volume":"99","author":"Allentuck","year":"1942","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biopsych.2015.11.018_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2015.11.018_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2015.11.018_bib10","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.11.018_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/42015","article-title":"A second endogenous cannabinoid that modulates long-term potentiation","volume":"388","author":"Stella","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2015.11.018_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"Lutz","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp","volume":"62","author":"Adams","year":"1940","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.biopsych.2015.11.018_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0091-3057(96)00426-1","article-title":"Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to a dysregulation of the endogenous cannabinoid system","volume":"56","author":"Emrich","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2015.11.018_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JCP.0b013e3181a6bc3b","article-title":"Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia","volume":"29","author":"Schwarcz","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/15622970801908047","article-title":"Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists","volume":"11","author":"Roser","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib18","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.biopsych.2015.11.018_bib19","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.11.018_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","article-title":"Pharmacological and molecular targets in the search for novel antipsychotics","volume":"11","author":"Scatton","year":"2000","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s002130050987","article-title":"Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils","volume":"144","author":"Poncelet","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.11.018_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0306-4522(98)00675-7","article-title":"Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function","volume":"91","author":"Alonso","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2015.11.018_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2015.11.018_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib27","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.11.018_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.biopsych.2015.11.018_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment","volume":"206","author":"Uriguen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.11.018_bib30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib31","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.11.018_bib32","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1523\/JNEUROSCI.21-07-02425.2001","article-title":"Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons","volume":"21","author":"Coutts","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib33","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib35","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1523\/JNEUROSCI.0442-05.2005","article-title":"Endocannabinoid signaling in rat somatosensory cortex: Laminar differences and involvement of specific interneuron types","volume":"25","author":"Bodor","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/jphysiol.2003.058198","article-title":"Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurones in juvenile mouse neocortex","volume":"556","author":"Trettel","year":"2004","journal-title":"J Physiol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib37","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1523\/JNEUROSCI.3027-04.2004","article-title":"Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors","volume":"24","author":"Galarreta","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI37335","article-title":"Schizophrenia from a neural circuitry perspective: Advancing toward rational pharmacological therapies","volume":"119","author":"Lewis","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopsych.2015.11.018_bib39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2015.11.018_bib40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2015.11.018_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","article-title":"Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial","volume":"134","author":"Boggs","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib42","unstructured":"Sanofi (2009): Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia (CONNECT). Available at: http:\/\/ClinicalTrials.gov\/show\/NCT00439634 NLM Identifier: NCT00439634. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/JCP.0b013e3182793843","article-title":"Effects of the cannabinoid-1 receptor antagonist\/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: A randomized, double-blind, pilot study","volume":"33","author":"Warren","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2015.11.018_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","article-title":"High-potency cannabis and the risk of psychosis","volume":"195","author":"Di Forti","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00023210-200418130-00005","article-title":"Cannabis-associated psychosis: Current status of research","volume":"18","author":"Leweke","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2015.11.018_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib51","first-page":"759","article-title":"Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum","volume":"34","author":"Bossong","year":"2009"},{"key":"10.1016\/j.biopsych.2015.11.018_bib52","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1063545","article-title":"Endocannabinoid signaling in the brain","volume":"296","author":"Wilson","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.11.018_bib53","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib54","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib55","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1046\/j.1432-1327.2001.02072.x","article-title":"The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors","volume":"268","author":"Bisogno","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.biopsych.2015.11.018_bib56","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.11.018_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3565(24)37365-3","article-title":"Comparative receptor binding analyses of cannabinoid agonists and antagonists","volume":"285","author":"Thomas","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.11.018_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.11.018_bib59","doi-asserted-by":"crossref","first-page":"PL1","DOI":"10.1016\/S0024-3205(98)00238-0","article-title":"Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors","volume":"63","author":"Petitet","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.60.1.155","article-title":"Evidence for a new G protein-coupled cannabinoid receptor in mouse brain","volume":"60","author":"Breivogel","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","article-title":"(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","volume":"456","author":"Pertwee","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib63","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib64","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \"atypical\" antipsychotic: A meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2015.11.018_bib67","unstructured":"University of Cologne (2008): A Clinical Trial on the Antipsychotic Properties of Cannabidiol. Available at: http:\/\/ClinicalTrials.gov\/show\/NCT00309413 NLM Identifier: NCT00309413. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib68","unstructured":"Yale University (2009): Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia. Available at: http:\/\/ClinicalTrials.gov\/show\/NCT00588731 NLM Identifier: NCT00588731. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib69","unstructured":"G. W. Research Ltd (2013): A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder. Available at: http:\/\/ClinicalTrials.gov\/show\/NCT02006628 NLM Identifier: NCT02006628. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib70","unstructured":"GW Pharmaceuticals plc (2015): GW Pharmaceuticals Announces Positive Proof of Concept Data in Schizophrenia. Available at: http:\/\/globenewswire.com\/news-release\/2015\/09\/15\/768364\/10149367\/en\/GW-Pharmaceuticals-Announces-Positive-Proof-of-Concept-Data-in-Schizophrenia.html?f=22&fvtc=3&fvtv=4000. Accessed: October 1, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib71","unstructured":"Central Institute of Mental Health (2015): A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients. Available at: http:\/\/ClinicalTrials.gov\/show\/NCT02088060 NLM Identifier: NCT02088060. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib72","unstructured":"King\u2019s College London (2013): Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders (CBD_ADD_IN). Available at: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-000240-26\/GB. EudraCT Number: 2013-000240-26. Accessed March 31, 2015."},{"key":"10.1016\/j.biopsych.2015.11.018_bib73","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2125.2011.04137.x","article-title":"Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects","volume":"73","author":"Li","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib74","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/jcbfm.2015.133","article-title":"Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: A positron emission tomography study with the novel radioligand [(11)C]CURB","volume":"35","author":"Boileau","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.11.018_bib75","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.2174\/138161212802884843","article-title":"Anandamide dysfunction in prodromal and established psychosis","volume":"18","author":"Leweke","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopsych.2015.11.018_bib76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid of initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib78","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/bpb.19.1109","article-title":"Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids","volume":"19","author":"Watanabe","year":"1996","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.biopsych.2015.11.018_bib79","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1124\/jpet.106.105247","article-title":"Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma","volume":"318","author":"Ligresti","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.11.018_bib80","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib81","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)35376-5","article-title":"Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells","volume":"292","author":"Rakhshan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.11.018_bib82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nn.2986","article-title":"A catalytically silent FAAH-1 variant drives anandamide transport in neurons","volume":"15","author":"Fu","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","article-title":"Time-dependent vascular actions of cannabidiol in the rat aorta","volume":"612","author":"O\u2019Sullivan","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib84","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1371\/journal.pmed.0030327","article-title":"Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia","volume":"3","author":"Holmes","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.biopsych.2015.11.018_bib85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2011.03.053","article-title":"Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia","volume":"222","author":"Gururajan","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0304-3940(97)00358-3","article-title":"Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia","volume":"228","author":"Liu","year":"1997","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2015.11.018_bib87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/sj.bjp.0701272","article-title":"Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture","volume":"121","author":"Docherty","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0091-3057(00)00201-X","article-title":"Different effects of nabilone and cannabidiol on binocular depth inversion in man","volume":"66","author":"Leweke","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2015.11.018_bib89","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.biopsych.2005.08.019","article-title":"Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: Therapeutic implications","volume":"59","author":"Tzavara","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.11.018_bib90","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1523\/JNEUROSCI.0315-14.2014","article-title":"Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission","volume":"34","author":"Fawley","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib91","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1016\/j.biopsych.2015.11.018_bib92","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib93","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and Delta (9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib94","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrn3937","article-title":"Weeding out bad waves: Towards selective cannabinoid circuit control in epilepsy","volume":"16","author":"Soltesz","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2015.11.018_bib95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2015.11.018_bib96","doi-asserted-by":"crossref","first-page":"20270","DOI":"10.1073\/pnas.0909411106","article-title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo","volume":"106","author":"Long","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.11.018_bib97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.neuroscience.2008.01.034","article-title":"Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain","volume":"152","author":"Palkovits","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2015.11.018_bib98","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-3-642-25761-2_7","article-title":"Medical needs in the treatment of psychotic disorders","volume":"212","author":"Leweke","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.biopsych.2015.11.018_bib99","series-title":"Cannabinoids in Neurologic and Mental Disease","first-page":"193","article-title":"Cannabinoids and schizophrenia","author":"Rohleder","year":"2015"},{"key":"10.1016\/j.biopsych.2015.11.018_bib100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1369-1600.2008.00106.x","article-title":"Cannabis and psychiatric disorders: it is not only addiction","volume":"13","author":"Leweke","year":"2008","journal-title":"Addict Biol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322315009956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322315009956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:55:34Z","timestamp":1748692534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322315009956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0006322315009956"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2015.11.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726136838.793528763","asserted-by":"object"}]},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}